Introduction
Methods
Study population
CCTA acquisition
CCTA assessment
Biomarker assessment
CCL assessment
Follow-up
Statistics
Results
Study population
<50 % stenosis | ≥50 % stenosis |
p-value | |
---|---|---|---|
n = 509 |
n = 203 | – | |
Age (years) | 54.7 ± 10.2 | 60.9 ± 9.3 |
<0.001
|
Male gender | 266 (52.3 %) | 132 (65.0 %) |
0.002
|
Smoking | 107 (21.0 %) | 62 (30.5 %) |
0.008
|
Diabetes mellitus | 41 (8.1 %) | 17 (8.4 %) | 0.88 |
Family history | 187 (36.7 %) | 85 (41.9 %) | 0.23 |
Systolic blood pressure (mm Hg) | 140 ± 17 | 147 ± 20 |
<0.001
|
BMI (kg/m2) | 26.9 ± 4.1 | 27.4 ± 4.4 | 0.14 |
LDL cholesterol (mmol/l) HDL cholesterol (mmol/l) Statin use | 3.3 ± 1.0 1.3 ± 0.5 167 (33.0 %) | 3.3 ± 1.2 1.3 ± 0.8 100 (49.5 %) | 0.67 0.51
<0.001
|
Typical chest pain | 59 (11.6 %) | 29 (14.3 %) | 0.32 |
Calcium score | 0 (0–24.5) | 201 (53.5–455) |
<0.001
|
Involvement score | 0 (0–2) | 5 (3–7) |
<0.001
|
CCL3 (pg/ml) | 2.5 (0.0–7.0) | 2.8 (0.4–7.0) | 0.37 |
CCL5 (pg/ml *102) | 33.4 (14.5–77.0) | 40.7 (18.5–109.1) |
0.02
|
CCL18 (pg/ml *102) hsCRP (mg/dl) | 747.1 (450.5–1241.3) 1.4 (0.7–1.4) | 885.1 (502.5–1331.8) 1.7 (0.9–4.1) | 0.06
0.02
|
Association CCL with CAD
Coronary calcium score (log-transformed) | |||
---|---|---|---|
B-value | 95 % CI |
p-value | |
Age (years) | 0.44 | 0.04–0.05 |
<0.001
|
Male gender | 0.14 | 0.15–0.47 |
<0.001
|
Smoking | 0.05 | −0.05–0.33 | 0.15 |
Diabetes mellitus | 0.10 | 0.12–0.70 |
0.006
|
Family history | 0.01 | −0.14–0.20 | 0.72 |
Systolic blood pressure (mm Hg) | 0.23 | 0.01–0.02 |
<0.001
|
BMI (kg/m2) | 0.06 | −0.00–0.04 | 0.09 |
LDL cholesterol (mmol/l) HDL cholesterol (mmol/l) Statin use | −0.05 −0.01 0.19 | −0.13–0.02 −0.16–0.12 0.27–0.59 | 0.17 0.75
<0.001
|
Typical chest pain | −0.01 | −0.28–0.20 | 0.75 |
Lg10 CCL3 | 0.04 | −0.09–0.28 | 0.33 |
Lg10 CCL5 | −0.02 | −0.11–0.07 | 0.60 |
Lg10 CCL18 Lg10 hsCRP ≥50 % stenosis | 0.12 0.03 0.57 | 0.16–0.73 −0.12–0.25 1.23–1.52 |
0.002
0.50
<0.001
|
Involvement score (log-transformed) | |||
B-value | 95 % CI |
p-value | |
Age (years) | 0.38 | 0.01–0.02 |
<0.001
|
Male gender | 0.20 | 0.09–0.19 |
<0.001
|
Smoking | 0.09 | 0.01–0.13 |
0.02
|
Diabetes mellitus | 0.10 | 0.03–0.22 |
0.01
|
Family history | 0.03 | −0.03–0.07 | 0.44 |
Systolic blood pressure (mm Hg) | 0.23 | 0.00–0.01 |
<0.001
|
BMI (kg/m2) | 0.03 | −0.00–0.01 | 0.39 |
LDL cholesterol (mmol/l) HDL cholesterol (mmol/l) Statin use | 0.00 −0.01 0.19 | −0.02–0.03 −0.05–0.04 0.09–0.19 | 0.94 0.80
<0.001
|
Typical chest pain | −0.00 | −0.08–0.08 | 0.97 |
Lg10 CCL3 | 0.04 | −0.03–0.10 | 0.25 |
Lg10 CCL5 | −0.03 | −0.04–0.02 | 0.46 |
Lg10 CCL18 Lg10 hsCRP ≥50 % stenosis | 0.10 0.03 0.66 | 0.03–0.22 −0.04–0.08 0.47–0.55 |
0.007
0.56
<0.001
|
OR | 95 % CI |
p-value | |
---|---|---|---|
Model 1
| |||
Lg10 CCL3 | 1.01 | 0.67–1.53 | 0.96 |
Lg10 CCL5 | 1.23 | 0.99–1.53 | 0.06 |
Lg10 CCL18 | 1.03 | 0.55–1.93 | 0.92 |
Model 2
| |||
Lg10 CCL3 | 0.96 | 0.62–1.47 | 0.84 |
Lg10 CCL5 | 1.27 | 1.02–1.59 |
0.04
|
Lg10 CCL18 | 1.06 | 0.56–2.03 | 0.86 |
CCL concentrations and events
Patients without event | Patients with event |
p-value | |
---|---|---|---|
n = 661 |
n = 51 | – | |
Age (years) | 56 ± 10 | 58 ± 11 | 0.29 |
Male gender | 361 (54.6 %) | 37 (72.5 %) |
0.01
|
Smoking | 147 (22.2 %) | 22 (43.1 %) |
0.002
|
Diabetes mellitus | 52 (7.9 %) | 6 (11.8 %) | 0.29 |
Family history | 252 (38.1 %) | 20 (39.2 %) | 0.88 |
Systolic blood pressure (mm Hg) | 142 ± 19 | 143 ± 20 | 0.67 |
BMI (kg/m2) | 27 ±4 | 27 ±4 | 0.81 |
Total cholesterol (mmol/l) HDL cholesterol (mmol/l) LDL cholesterol (mmol/l) Statin use | 5.4 ± 1.1 1.3 ± 0.6 3.3 ± 1.0 244 (37.1 %) | 5.3 ± 1.3 1.2 ± 0.4 3.3 ± 1.2 23 (45.1 %) | 0.61 0.10 0.79 0.29 |
Typical chest pain | 81 (12.3 %) | 7 (13.7 %) | 0.67 |
Calcium score | 4.6 (0.0–103.1) | 181.0 (20.6–458.2) |
<0.001
|
Involvement score | 1.0 (0.0–3.0) | 5.0 (2.0–7.0) |
<0.001
|
CCL3 (pg/ml) | 2.7 (0.0–7.0) | 2.7 (0.0–6.7) | 0.96 |
CCL5 (pg/ml *102) | 34.4 (15.0–79.6) | 55.6 (31.2–115.6) |
0.005
|
CCL18 (pg/ml *102) hsCRP ≥50 % stenosis | 769.0 (455.7–1266.0) 1.4 (0.7–3.1) 162 (24.5 %) | 941.4 (529.9–1272.1) 1.8 (1.1–4.1) 41 (80.4 %) | 0.23 0.07
<0.001
|
OR | 95 % CI |
p-value | |
---|---|---|---|
Model 1
| |||
Lg10 CCL3 | 0.81 | 0.41–1.60 | 0.54 |
Lg10 CCL5 | 1.71 | 1.07–2.73 |
0.03
|
Lg10 CCL18 | 1.33 | 0.45–3.98 | 0.61 |
Model 2
| |||
Lg10 CCL3 | 0.88 | 0.43–1.78 | 0.71 |
Lg10 CCL5 | 1.60 | 1.01–2.52 |
0.046
|
Lg10 CCL18 | 1.35 | 0.45–4.10 | 0.59 |
Model 3 (CT ≥50 %)
| |||
Lg10 CCL3 | 0.96 | 0.44–2.07 | 0.91 |
Lg10 CCL5 | 1.35 | 0.88–2.06 | 0.17 |
Lg10 CCL18 | 1.46 | 0.45–4.72 | 0.53 |
Model 4 (involvement score)
| |||
Lg10 CCL3 | 0.75 | 0.35–1.59 | 0.45 |
Lg10 CCL5 | 1.62 | 1.03–2.57 |
0.04
|
Lg10 CCL18 | 1.39 | 0.45–4.34 | 0.57 |